Metamizol for the Treatment of Neoplastic Chronic Pain

Analgesic Effect of a New Metamizol Oral Pharmaceutical Form for the Treatment of the Neoplastic Chronic Pain: Randomized, Double-blind Crossover Clinical Trial Between Metamizol, Diclofenac and Placebo

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02181920

Enrollment

Registered

2014-07-08

Start date

2000-03-31

Completion date

Unknown

Last updated

2014-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Brief summary

Study to evaluate the efficacy of metamizole in reducing morphine requirements in patients with moderate to severe chronic cancer pain in comparison to administration of placebo or diclofenac.

Interventions

DRUGMetamizole

DRUGDiclofenac

DRUGDiclofenac placebo

DRUGMetamizole placebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Hospitalized patients with neoplastic chronic pain requiring morphine treatment

Exclusion criteria

* Karnofsky index less than 30%

Design outcomes

Primary

Measure	Time frame
Change in morphine requirement	Baseline, 9 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026